(Enapotamab)Biosimilar Reference Antibody-GS40222 新品

货号：GS40222

Enapotamab (development code HuMax-AXL-ADC) is an investigational antibody-drug conjugate (ADC) developed for the treatment of solid tumors. It is engineered by linking a potent cytotoxic drug (a tubulin inhibitor) to a fully human monoclonal antibody via a cleavable linker. Enapotamab functions as a targeted chemotherapy agent, where the antibody component specifically delivers the cytotoxic payload to cancer cells expressing its target receptor. Upon binding, the ADC is internalized into the target cell, where the linker is cleaved, releasing the drug to disrupt microtubule formation, ultimately leading to tumor cell death.